Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
- Conditions
- Pancreatic CancerColorectal CancerGastric CancerOvarian Cancer
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Cue Biopharma
- Target Recruit Count
- 42
- Registration Number
- NCT05360680
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Stanford Advanced Medicine Cancer Center, Palo Alto, California, United States
A Phase 1 Study in Patients with HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck CancerHPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Related Carcinoma
- Interventions
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Cue Biopharma
- Target Recruit Count
- 85
- Registration Number
- NCT03978689
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Yale School of Medicine, New Haven, Connecticut, United States
News
CUE-101 Combination Therapy Achieves 50% Response Rate in HPV+ Head and Neck Cancer Trial
Cue Biopharma's CUE-101 combined with pembrolizumab demonstrated a 50% overall response rate in patients with recurrent/metastatic HPV+ head and neck squamous cell carcinoma, significantly outperforming historical pembrolizumab monotherapy data.
Cue Biopharma Receives Positive FDA Feedback for CUE-401 Autoimmune Therapy, Advances Toward IND Filing
Cue Biopharma received positive Pre-IND feedback from the FDA for CUE-401, a first-in-class bispecific fusion protein designed to treat autoimmune diseases by inducing regulatory T cells.
Boehringer Ingelheim and Cue Biopharma Partner on Novel B Cell-Targeting Therapy for Autoimmune Diseases
Boehringer Ingelheim and Cue Biopharma have formed a strategic partnership to develop CUE-501, a first-in-class bispecific therapy designed to selectively deplete disease-causing B cells in autoimmune conditions.
Cue Biopharma's CUE-101 and CUE-102 Show Promise in Phase 1 Trials for Head and Neck and WT1-Positive Cancers
CUE-101 combined with pembrolizumab demonstrates a 46% objective response rate and a 91.3% 12-month overall survival rate in first-line HPV+ R/M HNSCC patients.
Cue Biopharma's CUE-101 and CUE-102 Show Promising Phase 1 Results in Cancer Trials
Cue Biopharma's CUE-101, combined with pembrolizumab, demonstrated a 46% objective response rate and a 91.3% 12-month overall survival rate in head and neck cancer patients.
Cue Biopharma Announces Positive Phase 1 Data for CUE-101 and CUE-102 at SITC 2024
CUE-101 combined with pembrolizumab shows a 46% objective response rate and 91.3% 12-month overall survival in first-line HPV+ recurrent/metastatic head and neck squamous cell carcinoma patients.